MEDIPHARM LABS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 CAD | 0.00% |
|
0.00% | +23.08% |
| Mar. 27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5% | MT |
| Mar. 27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 505.1 | 82.44 | 50.06 | 19.75 | 26.08 | 32.32 | - |
| Enterprise Value (EV) 1 | 468.3 | 70.23 | 50.06 | 19.75 | 26.08 | 32.32 | 32.32 |
| P/E ratio | 386 x | -1.1 x | -0.84 x | -0.64 x | -1.63 x | -5.33 x | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.91 x | 2.29 x | 2.31 x | 0.89 x | 0.79 x | 0.75 x | 0.55 x |
| EV / Revenue | 3.91 x | 2.29 x | 2.31 x | 0.89 x | 0.79 x | 0.75 x | 0.55 x |
| EV / EBITDA | 20.2 x | -3.45 x | -1.88 x | -0.96 x | -2.55 x | -12.8 x | 6.92 x |
| EV / FCF | -8,753,588 x | -1,823,166 x | -3,576,401 x | -1,166,522 x | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 130,857 | 155,550 | 270,569 | 282,165 | 401,281 | 404,049 | - |
| Reference price 2 | 3.860 | 0.5300 | 0.1850 | 0.0700 | 0.0650 | 0.0800 | 0.0800 |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/26/24 | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 129.3 | 36.01 | 21.71 | 22.12 | 33.06 | 43.06 | 58.43 |
| EBITDA 1 | 24.97 | -23.87 | -26.68 | -20.57 | -10.22 | -2.518 | 4.669 |
| EBIT 1 | 6.938 | -72.58 | -32.32 | -29.53 | -18.25 | -8.114 | -0.4428 |
| Operating Margin | 5.37% | -201.53% | -148.85% | -133.53% | -55.21% | -18.84% | -0.76% |
| Earnings before Tax (EBT) 1 | 6.752 | -72.1 | -54.69 | -29.99 | -13.36 | -8.47 | -1.655 |
| Net income 1 | 1.645 | -66.35 | -54.8 | -29.98 | -13.08 | -7.27 | -1.655 |
| Net margin | 1.27% | -184.25% | -252.41% | -135.57% | -39.57% | -16.88% | -2.83% |
| EPS 2 | 0.0100 | -0.4800 | -0.2200 | -0.1100 | -0.0400 | -0.0150 | - |
| Free Cash Flow | -57.7 | -45.22 | -14 | -16.93 | - | - | - |
| FCF margin | -44.64% | -125.57% | -64.47% | -76.56% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/26/24 | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.401 | 5.743 | 4.877 | 4.362 | 7.262 | 5.616 | 5.843 | 9.583 | 8.505 | 9.131 | 9.441 | 10.39 | 11.19 | 12.04 | - |
| EBITDA 1 | -5.622 | -6.573 | -5.684 | -6.345 | -4.974 | -3.634 | -3.09 | -3.191 | -2.346 | -1.579 | -1.314 | -0.8654 | -0.3864 | -0.0019 | - |
| EBIT 1 | -7.456 | -8.956 | -7.504 | -9.069 | -8.046 | -4.914 | -3.333 | -7.629 | -4.355 | -2.935 | -2.726 | -2.277 | -1.798 | -1.363 | - |
| Operating Margin | -138.05% | -155.95% | -153.87% | -207.91% | -110.8% | -87.5% | -57.04% | -79.61% | -51.21% | -32.14% | -28.87% | -21.91% | -16.07% | -11.32% | - |
| Earnings before Tax (EBT) 1 | -7.486 | -21.76 | -7.457 | -8.987 | -7.93 | -5.615 | -3.088 | -2.703 | -4.33 | -3.238 | -2.777 | -2.328 | -1.899 | -1.465 | - |
| Net income 1 | -7.356 | -21.77 | -7.457 | -8.987 | -7.93 | -5.609 | -3.088 | -2.703 | -4.327 | -2.965 | -2.477 | -2.028 | -1.549 | -1.165 | - |
| Net margin | -136.2% | -379% | -152.9% | -206.03% | -109.2% | -99.88% | -52.85% | -28.21% | -50.88% | -32.47% | -26.24% | -19.52% | -13.85% | -9.67% | - |
| EPS 2 | -0.0300 | -0.0800 | -0.0300 | -0.0300 | -0.0300 | -0.0200 | -0.0100 | -0.0100 | -0.0100 | -0.0100 | -0.0100 | -0.005000 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/31/23 | 5/15/23 | 8/14/23 | 11/14/23 | 3/26/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 36.8 | 12.2 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -57.7 | -45.2 | -14 | -16.9 | - | - | - |
| ROE (net income / shareholders' equity) | 2.07% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 32.4 | 7.45 | 0.78 | 0.86 | - | - | - |
| Capex / Sales | 25.1% | 20.68% | 3.61% | 3.9% | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/26/24 | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.08
CAD
Average target price
0.1
CAD
Spread / Average Target
+25.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.08% | 23.61M | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- LABS Stock
- Financials MediPharm Labs Corp.
